Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck gardasil / Gardasil 9 — China sales ($M) ($M)
Form 8-K Table 3c / 3b Footnote (Gardasil/Gardasil 9 sales in China)
Latest, Q4 2025
0
Period ended Dec 31, 2025
Change on a year earlier
-100.0%
446 in Q4 2024
History
8 quarters
Since Q1 2024
Sources
1
Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gardasil / Gardasil 9 — China sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 0 | -100.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 0 | -100.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | -100.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 193 | -84.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q4 2024 | Dec 31, 2024 | 446 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2024 | Sep 30, 2024 | 517 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,312 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,253 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Merck Gardasil / Gardasil 9 — China sales ($M) ($M), quarterly Q1 2024–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_gardasil_china
See every metric in the Merck KPI table. Data updated Oct 26, 2026.